off-label Dupilumab use

Atopic Dermatitis (AD) Treatment Initiation and Monitoring
atopic dermatitis (AD)During the recent DERM2O22 NP/PA CME conference held July 28-31, 2022, Drs. David Cohen, Brad Glick, and Adam Friedman led a case-based panel discussion on atopic dermatitis (AD) treatment initiation and monitoring. This article provides a summary of their discussion and recommendations.  CASE 1 51-year-old male with a 20-year history of AD. The patient was first seen in September 2015 with BSA …
atopic dermatitis (AD)
Dupilumab Therapeutic Cheat Sheet
DupilumabAtopic dermatitis (AD) is a common skin condition characterized by pruritus and occurs as a result of factors related to impaired skin barrier and immune response, as well as environmental and infectious agents. Patients with poor control on topical therapy are looking for safe and effective systemic treatments. We continue our series, Therapeutic Cheat Sheet, with a closer look at dupilumab, whic …
Dupilumab